High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study

Rémi Coudroy1,2*, Angéline Jamet1, Philippe Petua1, René Robert1,2, Jean-Pierre Frat1,2 and Arnaud W. Thille1,2

Abstract
Background: Acute respiratory failure is the main cause of admission to intensive care unit in immunocompromised patients. In this subset of patients, the beneficial effects of noninvasive ventilation (NIV) as compared to standard oxygen remain debated. High-flow nasal cannula oxygen therapy (HFNC) is an alternative to standard oxygen or NIV, and its use in hypoxemic patients has been growing. Therefore, we aimed to compare outcomes of immunocompromised patients treated using HFNC alone or NIV as a first-line therapy for acute respiratory failure in an observational cohort study over an 8-year period. Patients with acute-on-chronic respiratory failure, those treated with standard oxygen alone or needing immediate intubation, and those with a do-not-intubate order were excluded.

Results: Among the 115 patients analyzed, 60 (52%) were treated with HFNC alone and 55 (48%) with NIV as first-line therapy with 30 patients (55%) receiving HFNC and 25 patients (45%) standard oxygen between NIV sessions. The rates of intubation and 28-day mortality were higher in patients treated with NIV than with HFNC (55 vs. 35%, p = 0.04, and 40 vs. 20%, p = 0.02 log-rank test, respectively). Using propensity score-matched analysis, NIV was associated with mortality. Using multivariate analysis, NIV was independently associated with intubation and mortality.

Conclusions: Based on this observational cohort study including immunocompromised patients admitted to intensive care unit for acute respiratory failure, intubation and mortality rates could be lower in patients treated with HFNC alone than with NIV. The use of NIV remained independently associated with poor outcomes.

Keywords: Acute respiratory failure, Immunosuppression, Noninvasive positive pressure ventilation, Acute lung injury, Mechanical ventilation, High-flow oxygen therapy

Background
Acute respiratory failure is the main cause of admission to intensive care unit (ICU) in immunocompromised patients [1]. In this subset of patients, the need for intubation and invasive mechanical ventilation is associated with particularly high mortality rates, reaching 70% of cases [2–4]. In the early 2000s, two randomized controlled trials reported lower rates of intubation and mortality with the use of noninvasive ventilation (NIV) as compared to standard oxygen [5, 6]. However, given the small samples of patients included in these studies, experts suggested that NIV could be used in immunocompromised patients with acute respiratory failure, but the strength of recommendation was assessed as weak [7]. As a consequence, so far NIV has been used as a first-line therapy in only 25–40% of immunocompromised patients admitted to ICU for acute respiratory...
failure [1, 8–10]. Recently, a large randomized controlled trial did not confirm the potential benefits of NIV and in fact found similar outcomes in immunocompromised patients with acute respiratory failure treated with NIV or oxygen alone [11]. It is important to note that, in this study, oxygen therapy could be delivered using either standard oxygen or high-flow oxygen through nasal cannula (HFNC).

HFNC is a recent technique that delivers heated and humidified oxygen at high-flow rates [12]. Several physiological studies have shown HFNC to be better tolerated than standard oxygen delivered through a mask [13–15]. High-flow rates of fresh gas help to increase the fraction of inspired oxygen (FiO₂) [16], to generate low levels of positive end-expiratory pressure [17], and to decrease physiological dead space by flushing expired carbon dioxide in the upper airways [18]. The result is a decrease in work of breathing [19] and dyspnea [14] while the heating and humidification of inspired gases may prevent thick secretions and atelectasis. HFNC could not only offer an alternative to standard oxygen in hypoxemic patients, but also avoid the need for NIV. In a recent multicenter randomized controlled trial, the mortality rate in patients with acute respiratory failure treated with HFNC alone was significantly lower in both those treated with standard oxygen and in those treated with NIV [20]. In this study, patients treated with NIV also received HFNC between NIV sessions, thereby suggesting a direct deleterious effect of NIV compared to the group receiving HFNC alone. That said, as patients with neutropenia were excluded from the trial, these results could not be extrapolated to all immunocompromised patients.

Given the fact that use of HFNC in patients with acute respiratory failure has been increasing in our unit over recent years, we aimed to compare the outcomes of immunocompromised patients treated with HFNC alone or with NIV as first-line therapy.

Some of the results of this study were reported in the form of an abstract at the 2016 meeting of the French Intensive Care Society in Paris, France.

Methods

Study design
Between 1 January 2007 and 31 December 2014, discharge reports from all patients admitted to our 15-bed medical ICU in a tertiary hospital were retrospectively reviewed. This study was approved by the Ethics Committee of the French Intensive Care Society (Société de Réanimation de Langue Française, SRLF, CE no. 14-27), and given its observational nature, informed consent was waived.

Screening of patients
We screened all patients admitted for acute respiratory failure defined by the following criteria: a respiratory rate ≥25 breaths/min or clinical signs of respiratory distress, and a calculated PaO₂-to-FiO₂ ratio ≤300 mmHg, FiO₂ being estimated as follows: (oxygen flow in liters per minute × 0.03) + 0.21 [20]. Among them, we included those who had immunosuppression caused by hematologic or solid cancer, stem cell or solid organ transplantation, a steroid dose of more than 0.5 mg/kg for at least 1 month, or cytotoxic drugs for non-malignant disease or acquired immune deficiency syndrome. Patients with acute-on-chronic respiratory failure, those treated with standard oxygen alone or needing immediate intubation, and those with a do-not-intubate order were excluded from the analysis.

Classification of patients
Patients were classified according to the time from the onset of acute respiratory failure and the start of the first-line strategy of ventilatory support including NIV or HFNC. All patients in whom NIV was started within the first 6 h after the onset of acute respiratory failure were included in the NIV group if they received at least 2 h of NIV within the first 24 h. Those who were treated with HFNC within the first 6 h after the onset of acute respiratory failure were included in the HFNC group, even if they received late NIV as a rescue therapy beyond the first 6 h. Therefore, patients initially treated with HFNC and who received late NIV as rescue therapy, i.e., the most severe patients, remained classified in the HFNC group. We excluded patients treated with standard oxygen during the first 6 h and who received short NIV (<2 h) considered as preoxygenation in case of frank respiratory worsening leading to intubation, and those treated with standard oxygen during the first 6 h and who received late NIV as rescue therapy. Each patient was classified by consensus of three senior intensivists (RC, JPF, and AWT) blinded to outcomes up to full agreement.

In our unit, the criteria to decide intubation were the same as those used in our previous studies [15, 20]: uncontrolled shock defined by mean arterial pressure ≤65 mm Hg despite a 30 ml/kg crystalloid fluid challenge and increasing doses of vasopressors, neurological impairment defined by a Glasgow score ≤12, or signs of persisting or worsening respiratory failure as defined by at least two of the following criteria: respiratory rate >40 breaths per minute, lack of improvement in signs of high respiratory muscle workload, development of copious tracheal secretions, acidosis with pH <7.35, an SpO₂ <90 % for more than 5 min without technical dysfunction, or a poor response to oxygenation techniques.
Data collection
For all included patients, we collected age, gender, functional status before ICU admission using the Knaus chronic health status score [21], Mac Cabe score reflecting the severity of underlying disease [22], severity scores including the Simplified Acute Physiology Score II [23], and the modified Sequential Organ Failure Assessment (excluding respiratory item) [24], type of immunosuppression, and year of ICU admission. Clinical, radiological, and biological parameters at inclusion such as heart rate, systolic blood pressure, respiratory rate, SpO2, body temperature, bilateral lung infiltrates on chest X-ray, arterial pH, sodium bicarbonate, and PaO2-to-FiO2 ratio were recorded. Two senior physicians reviewed all charts to assess the reason for acute respiratory failure (AJ and PP). Initial settings during NIV or HFNC and ventilation characteristics during the ICU stay were collected.

Outcomes
Primary end-point was the mortality rate at day 28. Secondary outcomes included intubation rate, length of mechanical ventilation and ICU stay, in-ICU mortality, and variables associated with intubation and mortality at day 28.

Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) or as median [interquartile range, from 25th to 75th percentiles] according to their distribution using the Kolmogorov–Smirnov test and compared using the Mann–Whitney or the Student’s t test as appropriate. Dichotomous variables were expressed in percentage and compared using the Fischer’s exact test or the Chi-square test as appropriate. Dichotomous variables were expressed in percentage and compared using the Fischer’s exact test or the Chi-square test as appropriate. Adjusted outcomes between patients who were or were not treated with NIV were compared using the paired t test or the Wilcoxon matched paired test as appropriate to compare adjusted outcomes. We considered two-tailed p values <0.05 as significant. Statistical analyses were performed using the statistical software package XLStat® (Addinsoft, Paris, France), GraphPadPrism 5® (La Jolla, CA, USA) and R statistical package (online at http://www.R-project.org).

Results
Of the 5244 patients admitted to our unit over an 8-year period, 1299 (25 %) were admitted for acute respiratory failure. Among them, 267 (21 %) were immunocompromised (Fig. 1). Baseline characteristics of the 115 patients (43 %) included in the analysis are given in Table 1. In the NIV group, patients were more likely to be male, to have hypercapnia and alkalemia at admission, whereas in the HFNC group they tended to be older. In the first half of the study period, patients were more likely to be treated with NIV as first-line therapy than in the second half: 68 % (26 of 38 patients) received NIV from 2007 versus 2010 versus 38 % (22 of the 77 patients) from 2011 to 2014, p = 0.003. Intubation rates in the NIV group did not differ between the 2 periods: 57 % (15/26 patients) in the first period versus 52 % (15/29) in the second one (p = 0.66).

In the NIV group, initial FiO2 was 0.6 [0.5–0.9], whereas levels of pressure support and positive end-expiratory pressure were 10 cm H2O [8–12] and 4 cm H2O [4–5], respectively. Mean expiratory tidal volume delivered during the first 24 h after NIV initiation was 9.0 ± 2.4 ml/kg of predicted body weight. NIV was applied during 2.0 days [1.0–4.0] in median for a duration of 8 h [4–11] during the first 24 h. Among the 55 patients treated with NIV, 25 patients (45 %) received standard oxygen between NIV sessions, whereas the 30 other patients (55 %) received HFNC.

In the HFNC group, FiO2 was 0.6 [0.5–1], whereas gas flow was 50 l/min [40–50]. HFNC was applied continuously for a total duration of 2.0 days [1.0–4.0] in median. Eight patients in the HFNC group (13 %) received NIV as rescue therapy during their ICU stay.

Overall intubation rate was 44 % (51 of 115 patients), and overall mortality at day 28 was 30 % (34 of 115 patients). The rates of intubation and of mortality in ICU and at day 28 were significantly lower in the HFNC group than in the NIV group (Table 1 and Fig. 2). Mortality of patients who needed intubation tended to be significantly lower in the HFNC group (9/21 patients, 43 %) than in the NIV group (21/30 patients, 70 %, p = 0.05).

In the NIV group, outcomes did not significantly differ between the patients who received HFNC between
NIV sessions and those who received standard oxygen: the rates of intubation were 47 % (14/30) versus 64 % (16/25), respectively, p = 0.28; the rates of mortality at day 28 were 36 % (11/30) versus 44 % (11/25), respectively, p = 0.59.

Variables associated with intubation and mortality at day 28 in the overall population are given in Additional file 1 and Table 2, respectively. Using multivariate analysis, the 3 variables independently associated with intubation were severity at admission in the ICU as indicated by a high SAPS II, need for vasopressor within the 24 h after ICU admission, and use of NIV (Table 3). Use of NIV remained associated with mortality at day 28 independently from age and the need for vasopressor within 24 h after ICU admission (Table 3), even after forcing the year of admission in the model.

Baseline characteristics and outcomes of the 57 patients included in the propensity score-matched cohort are displayed in Table 4. In-ICU mortality at day 28 remained significantly lower in the HFNC than in the NIV group after matching on age and need for vasopressors within 24 h after ICU admission (Table 4). Using multivariate analysis in the matched cohort, NIV as a first-line therapy was the only factor independently associated with mortality at day 28 with and adjusted odds ratio of 4.03 and a 95 % confidence interval of [1.09–14.93], even after forcing the year of ICU admission.

Discussion

Our main finding is that immunocompromised patients admitted to ICU for acute respiratory failure had higher mortality when treated with NIV than those treated with HFNC alone. Moreover, they were more likely to be intubated and to have prolonged ICU length of stay. After adjustment, NIV remained independently associated with intubation and mortality at day 28.

In our study, intubation and mortality rates in the NIV group of the overall cohort were 55 and 40 %, respectively. These results are in keeping with the intubation and mortality rates reported in recent cohort studies [2,
Table 1  Comparison of baseline characteristics and outcomes between patients treated by noninvasive positive pressure ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen therapy alone

|                                | NIV (n = 55) | HFNC (n = 60) | p value |
|--------------------------------|--------------|---------------|---------|
| Age (years)                    | 58 (44–66)   | 62 (50–70)    | 0.06    |
| Gender (male)                  | 42 (76 %)    | 35 (58 %)     | 0.048   |
| Knaus chronic health status score |              |               | 0.46    |
| A                              | 15 (27 %)    | 19 (32 %)     |         |
| B                              | 17 (31 %)    | 22 (37 %)     |         |
| C                              | 21 (38 %)    | 15 (25 %)     |         |
| D                              | 2 (3.6 %)    | 4 (6.7 %)     |         |
| Mac Cabe classification        |              |               | 0.20    |
| 1                              | 20 (36 %)    | 19 (32 %)     |         |
| 2                              | 19 (35 %)    | 30 (50 %)     |         |
| 3                              | 16 (29 %)    | 11 (18 %)     |         |
| SAPS II at ICU admission (points) | 42 ± 11   | 46 ± 13       | 0.10    |
| Modified SOFA score at inclusion (points) | 3 (1–6)   | 4 (1–6)       | 0.28    |
| Type of immunosuppression      |              |               | 0.30    |
| Hematologic cancer or neutropenia | 33 (60 %)  | 31 (52 %)     |         |
| Solid cancer                   | 11 (20 %)    | 8 (13 %)      |         |
| Drug-induced immunosuppression | 10 (18 %)    | 20 (33 %)     |         |
| Acquired immune deficiency syndrome | 1 (2 %)    | 1 (2 %)       |         |
| Cause of respiratory failure   |              |               | 0.38    |
| Documented infection            | 24 (44 %)    | 31 (52 %)     |         |
| Cardiogenic pulmonary edema    | 5 (9 %)      | 5 (8 %)       |         |
| Specific                       | 13 (24 %)    | 6 (10 %)      |         |
| Other identified causes        | 7 (13 %)     | 11 (18 %)     |         |
| Not identified cause           | 6 (11 %)     | 7 (12 %)      |         |
| Clinical and biological parameters at inclusion |          |               |         |
| Heart rate (beats/min)         | 111 ± 22     | 113 ± 23      | 0.71    |
| Systolic blood pressure (mmHg) | 130 (113–150) | 119 (110–147) | 0.28    |
| Respiratory rate (breaths/min) | 30 (26–33)   | 29 (26–32)    | 0.75    |
| SpO2 (%)                       | 94 (91–98)   | 96 (94–99)    | 0.02    |
| Body temperature (°C)          | 37.8 ± 1.1   | 38.0 ± 1.1    | 0.47    |
| Bilateral lung infiltrates on chest X-ray | 46 (84 %) | 50 (83 %) >0.99 |
| Arterial pH                    | 7.44 (7.40–7.47) | 7.46 (7.43–7.50) | 0.02 |
| PaO2-to-FiO2 ratio (mmHg)      | 141 (111–177)| 149 (107–204)| 0.19 |
| PaO2-to-FiO2 ratio ≤ 200 mmHg  | 47 (85 %)   | 44 (73 %)    | 0.17    |
| PaCO2 (mmHg)                   | 37 (32–45)   | 32 (29–38)    | <0.0001 |
| PaCO2 > 45 mmHg                | 12 (22 %)    | 2 (3 %)       | 0.003   |
| Sodium bicarbonate (mmol/l)    | 25 (22–28)   | 21 (24–26)    | 0.04    |
| Vaspressors within 24 h after ICU admission | 9 (16 %) | 14 (23 %) | 0.35 |
| Time from admission to ventilatory support initiation (h) | 1 (0–1) | 1 (0–1) | 0.62 |
| Need for immunosuppressive drug during ICU stay | 13 (24 %) | 15 (25 %) | >0.99 |
| Admission before 2011           | 26 (47 %)    | 12 (20 %)     | <0.0001 |
| Primary outcome                |              |               |         |
| 28-day mortality               | 22 (40 %)    | 12 (20 %)     | 0.02    |
| Secondary outcomes             |              |               |         |
| Intubation                      | 30 (55 %)    | 21 (35 %)     | 0.04    |
| Time from admission to intubation (h) | 28 (18–49) | 35 (9–49) | 0.99 |
| Length of invasive mechanical ventilation (days) | 8 (4–11) | 7 (4–12) | 0.63 |
| Length of ICU stay (days)      | 8 (5–13)     | 7 (4–9)       | 0.08    |
| In-ICU mortality                | 20 (36 %)    | 9 (15 %)      | 0.01    |

Nominal variables are given as number (%), and continuous data are given as median (25th–75th percentile) or mean ± standard deviation (SD) according to their distribution using the Kolmogorov-Smirnov test.

SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
reinforcing the external validation of our results. Conversely, the rates of intubation and mortality in our patients treated with HFNC alone were 35 and 20 %, respectively, which are markedly lower than the rates reported in the above-mentioned studies [2, 26–28]. Therefore, these differences seem more likely due to a decrease in intubation or mortality rates observed in the HFNC group rather than an excess of intubation or mortality in the NIV group.

In contrast to patients with chronic obstructive pulmonary disease [29, 30] or cardiogenic pulmonary edema [31], the benefits of NIV remain unclear in immunocompromised patients with acute respiratory failure. To date, three randomized controlled trials have compared the use of NIV versus standard oxygen in immunocompromised patients with acute respiratory failure [5, 6, 11]. In a first trial including 40 patients with solid organ transplantation, the rate of intubation was significantly reduced in patients treated with NIV [5]. However, nearly one quarter of the patients had cardiogenic pulmonary edema [5], a condition for which the benefits of NIV are supported by a strong level of evidence [31]. In a second trial including 52 patients, the rates of intubation and mortality were significantly lower in patients treated with NIV [6]. However, these beneficial effects were observed only in patients with hematologic cancer or neutropenia, which accounted for 15 patients per group [6]. In the most recent trial including 374 patients, intubation and mortality rates did not differ between the two groups [11]. However, respiratory rate and oxygen requirement at inclusion were lower than in our study and in the two previous trials [5, 6], perhaps illustrating a lower severity of respiratory failure, which may have attenuated the impact of NIV on outcomes.

The case volume of patients treated with first-line NIV may also have influence on outcomes, with lower expected intubation rates in highly skilled centers. These findings have already been suggested in patients treated with NIV for cardiogenic pulmonary edema or acute-on-chronic respiratory failure [9, 32–35]. In our high case-volume center, this would have favoured the NIV group and attenuated the outcome difference between the 2 groups, which was not the case.

A recent retrospective study including 178 immunocompromised patients with acute respiratory failure suggested that the best strategy consisted in use of NIV associated with HFNC between NIV sessions [28]. The 37 % mortality rate recorded in the group treated by NIV and HFNC was almost the same as that of our patients treated by NIV (40 %). Once again, this mortality rate remained markedly higher than the 20 % rate we report herein in our patients treated with HFNC alone. Therefore, use of HFNC alone without NIV could be the treatment of choice in immunocompromised patients admitted to ICU for acute respiratory failure.

Although use of HFNC alone has been poorly evaluated in immunocompromised patients with acute respiratory failure, our results are in line with those found recently in a large multicenter randomized controlled trial [20]. Indeed, this study showed a significantly reduced mortality rate in patients treated with HFNC alone as compared to those treated by NIV with HFNC between NIV sessions [20]. In this trial, about one-third of included patients were immunocompromised, and the rates of intubation and in-ICU mortality in the HFNC group were 38 and 11 %, respectively, which are in line with those we report.

The beneficial effects of HFNC could be largely due to tolerance. HFNC seems better tolerated than NIV in patients with acute respiratory failure with a higher degree of comfort, a reduction in the severity of dyspnea and a decreased respiratory rate [15, 20]. Although these criteria were not assessed in our study, we believe that our findings may be extrapolated to immunocompromised patients. By contrast, NIV could be harmful due to potential ventilator-induced lung injury generated by pressure support that increases tidal volumes [36] and leads to high transpulmonary pressure [37]. Indeed, it
Table 2 Univariate analysis of variables associated with mortality at day 28 in the overall population

| Variable                                                                 | Survivors (n = 81) | Non-survivors (n = 34) | Odds ratio (95 % CI) | p value |
|--------------------------------------------------------------------------|--------------------|------------------------|----------------------|---------|
| Demographic variables                                                   |                    |                        |                      |         |
| Age (years)                                                             | 56 ± 15            | 60 ± 15                | 1.02 (0.99–1.05)     | 0.13    |
| Gender (male)                                                           | 54 (67 %)          | 23 (68 %)              | 0.96 (0.41–2.25)     | 0.92    |
| ICU admission before 2011                                               | 24 (30 %)          | 14 (41 %)              | 1.66 (0.72–3.82)     | 0.23    |
| Noninvasive ventilation as a first-line therapy                         | 34 (42 %)          | 22 (65 %)              | 2.67 (1.16–6.12)     | 0.03    |
| SAPS II score                                                           | 42 ± 12            | 47 ± 13                | 1.036 (1.00–1.07)    | 0.04    |
| Modified SOFA score excluding respiratory item                          | 3 (1–6)            | 4 (1–7)                | 1.06 (0.93–1.21)     | 0.44    |
| Knaus chronic health status score                                       |                    |                        |                      | 0.32    |
| A                                                                        | 24 (30 %)          | 10 (29 %)              | 1                    |         |
| B                                                                        | 31 (38 %)          | 8 (24 %)               | 0.62 (0.21–1.81)     |         |
| C                                                                        | 23 (28 %)          | 13 (38 %)              | 1.36 (0.50–3.70)     |         |
| D                                                                        | 3 (3.7 %)          | 3 (8.8 %)              | 2.40 (0.41–13.98)    |         |
| Mac Cabe classification                                                 |                    |                        |                      | 0.32    |
| 1                                                                       | 28 (35 %)          | 11 (32 %)              | 1                    |         |
| 2                                                                       | 37 (46 %)          | 12 (35 %)              | 0.83 (0.32–2.14)     |         |
| 3                                                                       | 16 (20 %)          | 11 (32 %)              | 1.75 (0.62–4.94)     |         |
| Type of immunosuppression                                               |                    |                        |                      | 0.08    |
| Hematologic cancer or neutropenia                                       | 49 (60 %)          | 15 (44 %)              | 1                    |         |
| Solid cancer                                                            | 9 (11 %)           | 10 (29 %)              | 3.53 (1.21–10.27)    |         |
| Drug-induced immunosuppression                                          | 21 (26 %)          | 9 (26 %)               | 1.41 (0.54–3.70)     |         |
| Acquired immune deficiency syndrome                                     | 2 (2 %)            | 0 (0 %)                | 0.64 (0.02–27.52)    |         |
| Variables at inclusion                                                  |                    |                        |                      |         |
| Heart rate (bpm)                                                       | 111 ± 23           | 113 ± 21               | 1.00 (0.99–1.02)     | 0.71    |
| Systolic arterial blood pressure (mmHg)                                 | 126 ± 24           | 126 ± 29               | 1.00 (0.98–1.02)     | 0.96    |
| Diastolic arterial blood pressure (mmHg)                                | 67 ± 18            | 67 ± 13                | 1.00 (0.98–1.02)     | 0.99    |
| Respiratory rate (breaths/min)                                          | 28 (25–32)         | 30 (27–34)             | 1.04 (0.98–1.10)     | 0.19    |
| SpO₂ (%)                                                                | 96 (94–99)         | 94 (90–97)             | 0.90 (0.83–0.97)     | 0.01    |
| Body temperature (°C)                                                   | 38.0 ± 1.2         | 37.7 ± 0.9             | 0.82 (0.58–1.18)     | 0.29    |
| pH                                                                      | 7.46 (7.42–7.49)   | 7.44 (7.40–7.49)       | 0.59 (0.00–21.07)    | 0.30    |
| Sodium bicarbonate (mmol/l)                                             | 24 (22–27)         | 24 (22–27)             | 1.03 (0.94–1.12)     | 0.83    |
| PaO₂-to-Fio₂ ratio (mmHg)                                               | 158 ± 59           | 141 ± 48               | 0.99 (0.99–1.00)     | 0.15    |
| PaO₂-to-Fio₂ ratio ≤ 200 mmHg                                           | 62 (77 %)          | 29 (85 %)              | 1.78 (0.60–5.23)     | 0.29    |
| PaO₂ (mmHg)                                                             | 74 (61–88)         | 70 (57–93)             | 1.00 (0.99–1.01)     | 0.38    |
| PaCO₂ (mmHg)                                                            | 34 (31–40)         | 34 (31–45)             | 1.01 (0.97–1.06)     | 0.56    |
| PaCO₂ > 45 mmHg                                                         | 8 (10 %)           | 6 (18 %)               | 1.96 (0.62–6.14)     | 0.24    |
| Bilateral lung infiltrate                                               | 69 (85 %)          | 27 (79 %)              | 0.67 (0.24–1.89)     | 0.45    |
| Vasopressors within 24 h after ICU admission                            | 10 (12 %)          | 13 (38 %)              | 2.18 (0.85–5.62)     | 0.11    |
| Immunosuppressive drug during ICU stay                                  | 22 (27 %)          | 6 (17 %)               | 0.58 (0.21–1.58)     | 0.35    |
| Cause of respiratory failure                                           |                    |                        |                      | 0.13    |
| Documented infection                                                    | 38 (47 %)          | 17 (50 %)              | 1                    |         |
| Cardiogenic pulmonary edema                                             | 10 (12 %)          | 0 (0 %)                | 0.11 (0.01–2.17)     |         |
| Specific                                                                | 11 (14 %)          | 8 (24 %)               | 1.63 (0.56–4.76)     |         |
| Other identified causes                                                 | 12 (15 %)          | 6 (18 %)               | 1.14 (0.37–3.54)     |         |
| Not identified cause                                                    | 10 (12 %)          | 3 (9 %)                | 0.73 (0.19–2.91)     |         |

Nominal variables are given as number (%), and continuous data are given as median (25th–75th percentile) or mean ± standard deviation (SD) according to their distribution using the Kolmogorov–Smirnov test.

SAPS: Simplified Acute Physiology Score, SOFA: Sequential Organ Failure Assessment.
is well established that mortality of patients with acute respiratory distress syndrome (ARDS) is lower using low tidal volumes approximating 6 ml/kg of predicted body weight [38]. Even in patients without criteria for ARDS, the use of low tidal volumes may reduce the risk of developing ARDS [39]. In our study, the majority of patients treated with NIV had clinical criteria for ARDS according to the recent definition [40], and the expiratory tidal volumes delivered to these patients under NIV were around 9.0 ml/kg of predicted body weight. Although such high volumes are similar to those reported in recent studies focusing on NIV in acute respiratory failure [20, 34], they could be particularly deleterious by worsening lung injury. Indeed, in the study by Carteaux and colleagues, an expired tidal volume above 9.5 ml/kg of predicted body weight was a strong predictor of NIV failure in hypoxemic patients [36]. Despite the absence of expired tidal volume assessment in the HFNC group, the higher intubation rate observed in the NIV group may be explained by the high proportion of patients with an expired tidal volume above 9.5 ml/kg of predicted body weight (46 % of the patients treated with NIV). In addition, any potential deleterious effect of delayed intubation in patients treated with NIV [41, 42] can be ruled out as time from ICU admission to intubation was not longer than in patients treated with HFNC alone.

Limitations
Our study has several limitations. First, the study was monocentric and performed in a unit with experience in noninvasive management of immunocompromised patients with acute respiratory failure. Indeed, each year about 15 immunocompromised patients are treated with first-line noninvasive ventilatory support, which is close to the number of patients admitted in other highly skilled centers [2, 26]. Therefore, these results could not be extrapolated to centers with less experience. Second, the retrospective nature of the study might have induced selection bias despite the careful classification of patients included in the analysis. Indeed, the baseline characteristics of patients were not similar as patients in the HFNC group were older and as there was a higher proportion of patients with respiratory acidosis in the NIV group. NIV could have been preferentially used in hypercapnic patients due to its efficacy in correction of alveolar hypventilation [43]. Therefore, the most severe patients might have been more frequently treated with NIV than with HFNC alone. Nevertheless, functional status before ICU admission and baseline severity scores were similar between the two groups. Our intubation and mortality rates in the NIV group were similar to those reported in the literature [2, 6, 26, 27], thereby reinforcing the external validity of our results. Third, it is possible that outcomes of immunocompromised patients admitted to our ICU over this 8-year period had improved in the recent years [44]. However, even after forcing the year of ICU admission in the logistic regression model, NIV remained associated with intubation and mortality. Obviously, these results do

Table 3 Multivariate analysis of variables associated with outcomes in the overall population

| Variables independently associated with intubation<sup>a</sup> | Adjusted odds ratio (95 % CI) | p value |
|-------------------------------------------------------------|-------------------------------|---------|
| Simplified Acute Physiology Score II, per point             | 1.04 (1.00–1.08)              | 0.04    |
| Noninvasive ventilation as a first-line therapy              | 3.25 (1.39–7.60)              | 0.007   |
| Use of vasopressors within 24 h after ICU admission         | 4.12 (1.32–12.84)             | 0.02    |

* Non-collinear variables included in the logistical regression model were Simplified Acute Physiology Score II, Noninvasive ventilation as a first-line therapy, use of vasopressors within 24 h after ICU admission, SpO2 at ICU admission, cause of respiratory failure and PaCO2 as a continuous variable. The year of ICU admission was forced in the model

| Variables independently associated with mortality at day 28<sup>b</sup> | Adjusted odds ratio (95 % CI) | p value |
|------------------------------------------------------------------------|-------------------------------|---------|
| Age (per year)                                                          | 1.03 (1.00–1.07)              | 0.04    |
| Use of vasopressors within 24 h after ICU admission                     | 2.83 (1.02–7.91)              | 0.047   |
| Noninvasive ventilation as a first-line therapy                         | 3.70 (1.49–9.19)              | 0.005   |

* Non-collinear variables included in the logistical regression model were age, PaO2-to-FiO2 ratio at ICU admission, use of noninvasive ventilation as a first-line therapy, type of immunosuppression, use of vasopressors in the 24 h after ICU admission, cause of respiratory failure and PaCO2 > 45 mmHg. The year of ICU admission was forced in the model
Table 4 Comparison of baseline characteristics and outcomes between propensity score-matched patients treated by noninvasive positive pressure ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen therapy alone

|                                | NIV (n = 24) | HFNC (n = 33) | p value |
|--------------------------------|--------------|---------------|---------|
| Age (years)                    | 62 ± 11      | 62 ± 11       | 0.72    |
| Gender (male)                  | 18 (75 %)    | 17 (52 %)     | 0.13    |
| Knaus chronic health status score |             |               | 0.53    |
| A                              | 8 (33 %)     | 9 (27 %)      |         |
| B                              | 6 (25 %)     | 11 (33 %)     |         |
| C                              | 10 (42 %)    | 11 (33 %)     |         |
| D                              | 0 (0.0 %)    | 2 (6.1 %)     |         |
| Mac Cabe classification        |              |               | 0.27    |
| 1                              | 11 (46 %)    | 12 (36 %)     |         |
| 2                              | 6 (25 %)     | 15 (45 %)     |         |
| 3                              | 7 (29 %)     | 6 (18 %)      |         |
| SAPS II at ICU admission (points) | 40 ± 11      | 44 ± 12      | 0.52    |
| Modified SOFA score at inclusion (points) | 1.5 (0.0–4.0) | 3.0 (1.0–6.0) | 0.44 |
| Type of immunosuppression      |              |               | 0.19    |
| Hematologic cancer or neutropenia | 12 (50 %)    | 18 (55 %)    |         |
| Solid cancer                   | 7 (29 %)     | 3 (9.1 %)     |         |
| Drug-induced immunosuppression | 5 (21 %)     | 11 (33 %)     |         |
| Acquired immune deficiency syndrome | 0 (0.0 %)    | 1 (3.0 %)     |         |
| Cause of respiratory failure   |              |               | 0.08    |
| Documented infection           | 9 (38 %)     | 19 (58 %)     |         |
| Cardiogenic pulmonary edema    | 4 (27 %)     | 3 (9.1 %)     |         |
| Specific                       | 6 (25 %)     | 1 (3.0 %)     |         |
| Other identified causes        | 2 (8.3 %)    | 6 (18 %)      |         |
| Not identified cause           | 3 (13 %)     | 4 (12 %)      |         |
| Clinical and biological parameters at inclusion |         |               |         |
| Heart rate (beats/min)         | 107 ± 21     | 112 ± 21      | 0.55    |
| Systolic blood pressure (mmHg) | 140 ± 22     | 127 ± 23      | 0.17    |
| Respiratory rate (breaths/min) | 30 ± 6       | 29 ± 6        | 0.76    |
| SpO2 (%)                       | 94 ± 5       | 96 ± 4        | 0.10    |
| Body temperature (°C)          | 37.9 ± 1.1   | 37.9 ± 1.1    | 0.66    |
| Bilateral lung infiltrates on chest X-ray | 19 (79 %) | 31 (93 %) | 0.12 |
| Arterial pH                    | 7.45 ± 0.07  | 7.46 ± 0.06   | 0.43    |
| PaO2-to-FiO2 ratio (mmHg)      | 154 ± 57     | 156 ± 57      | 0.98    |
| PaO2-to-FiO2 ratio ≤ 200 mmHg  | 18 (75 %)    | 24 (73 %)     | 0.85    |
| PaCO2 (mmHg)                   | 39 ± 8       | 33 ± 5        | 0.03    |
| PaCO2 > 45 mmHg                | 4 (17 %)     | 1 (3.0 %)     | 0.15    |
| Sodium bicarbonate (mmol/l)    | 26 ± 4       | 24 ± 4        | 0.10    |
| Vasopressors within 24 h after ICU admission | 1 (4.2 %) | 4 (12 %) | 0.39 |
| Time from admission to ventilatory support initiation (h) | 1 (0–1) | 1 (0–1) | 0.98 |
| Need for immunosuppressive drug during ICU stay | 5 (21 %) | 4 (12 %) | 0.47 |
| Admission before 2011          | 12 (50 %)    | 7 (21 %)      | 0.04    |
| Primary outcome                |              |               |         |
| 28-day mortality               | 10 (42 %)    | 5 (15 %)      | 0.03    |
| Secondary outcomes             |              |               |         |
| Intubation                     | 13 (54 %)    | 10 (30 %)     | 0.07    |
| Mortality of intubated         | 10/13 (77 %) | 4/10 (40 %)   | 0.07    |
| Time from admission to intubation (h) | 48 (20–78) | 35 (22–59) | >0.99 |
| Length of invasive mechanical ventilation (days) | 8 (5–18) | 5 (3–10) | >0.99 |
not allow for definitive conclusion on the deleterious effects of NIV in this population, and our findings need to be confirmed in a randomized trial.

Conclusion

Based on this retrospective cohort study, the use of high-flow oxygen therapy through nasal cannula alone may be associated with better outcomes than noninvasive ventilation in immunocompromised patients admitted to intensive care unit for acute respiratory failure.

Additional file

**Additional file 1.** Univariate analysis of variables associated with intubation in the overall population.

**Abbreviations**

HFNC: high-flow oxygen therapy through nasal cannula; ICU: intensive care unit; NIV: noninvasive ventilation.

**Authors’ contributions**

RC, AJ, PF, RR AWI, and JPF participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

**Author details**

1 Service de Réanimation Médicale, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France. 2 INSERM CIC 1402 (ALIVE Group), Université de Poitiers, Poitiers, France.

**Acknowledgements**

We gratefully thank Jeffrey Arsham for editing the original manuscript.

**Competing interests**

The authors declare they have no competing interests.

**Ethics approval**

This study was approved by the Ethics Committee of the French Intensive Care Society (Societé de Réanimation de Langue Française, SRLF, CE no. 14-27) and given its observational nature, informed consent was waived.

**Received:** 31 January 2016  **Accepted:** 6 May 2016  **Published online:** 20 May 2016

**References**

1. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchou A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31(22):2810–8.

2. Azevedo LC, Caruso R, Silva UV, Torelly AP, Silva E, Rezende E, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest. 2014; Epub 2014/02/01.

3. Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J, Granada RM, et al. Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care. 2012;16(4):R133.

4. Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay E. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med. 2008;36(10):2766–72.

5. Antonelli M, Conti G, Biffi M, Costa MG, Lappa A, Rocco M, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. JAMA. 2000;283(2):235–41.

6. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344(7):481–7.

7. Keenan SP, Sinuff T, Burns KE, Muscedere J, Kutsogiannis J, Mehta S, et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ. 2011;183(3):E195–214.

8. Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchou A, Perez P, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med. 2014;40(4):582–91.

9. Schnell D, Timsit JF, Darmon M, Vesin A, Goldgran-Toledano D, Dumenil AS, et al. Noninvasive mechanical ventilation in acute respiratory failure: trends in use and outcomes. Intensive Care Med. 2014;40(4):582–91.

10. Demoule A, Chevret S, Carlucci A, Kouatchou A, Jaber S, Meziangi F, et al. Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. Intensive Care Med. 2016;42(11):82–92.

11. Lemiale V, Mokart D, Resche-Rigon M, Pene F, Mayaux J, Faucher E, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314(16):1711–9.

12. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest. 2015;148(1):253–61.

13. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011;37(11):1780–6.

14. Roca O, Riera J, Torres F, Mascans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010;55(4):408–13.

15. Frat JP, Brugiere B, Ragot S, Chatellier D, Veinstein A, Goulet V, et al. Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. Respir Care. 2015;60(2):170–8.

16. Sim MA, Dean P, Kinsella J, Black R, Carter R, Hughes M. Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated. Anaesthesia. 2008;63(9):938–40.

17. Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth. 2009;103(6):886–90.

18. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med. 2009;103(10):1400–5.

19. Vargas F, Saint-Leger M, Boyer A, Bui NH, Hilbert G. Physiologic effects of high-flow nasal cannula oxygen in critical care subjects. Respir Care. 2015;60(10):1369–76.
20. Frat JP, Thille AW, MercaT A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2013;372(23):2185–96.
21. Kraus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981;9(8):591–7.
22. McCabe WR, Jackson GG. Gram negative bacteremia: I. Etiology and ecology. Arch Intern Med. 1962;110:845–7.
23. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957–63.
24. Vincent JL, Moreno R, Takala J, Willumsen L,ej R, Sjölin M, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.
25. D’Agostino RB Jr, D’Agostino RB Sr. Estimating treatment effects using observational data. JAMA. 2007;297(3):314–6.
26. Mokart D, Geay C, Chow-Chine L, Brun JP, Faucher M, Blache JL, et al. Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. Respir Med. 2014;108(11):1509–16.
27. Griswold EM, Pontoppidan KM, Antin JH, Zhang J, Hewitt C, Shulman G, et al. The impact of noninvasive ventilation on outcome in patients with acute respiratory failure: A 5-year multicenter observational study. Crit Care Med. 2011;39(10):2232–9.
28. Mokart D, Geay C, Chow-Chine L, Brun JP, Faucher M, Blache JL, et al. Noninvasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. Respir Med. 2012;106(11):1509–16.
29. Vincent JL, Knaus WA, Salm S, et al. The APACHE II classification system to describe organ dysfunction/failure. Crit Care Med. 1991;19(1):760–8.
30. Mokart D, Geay C, Chow-Chine L, Brun JP, Faucher M, Blache JL, et al. Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. Respir Med. 2012;106(11):1509–16.
31. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013;5:CD000351.
32. Contou D, Fragnoli C, Cordoba-Izquierdo A, Boissier F, Brun-Buisson C, Thille AW. Noninvasive ventilation for acute hypercapnic respiratory failure: intubation rate in an experienced unit. Respir Care. 2013;58(12):2045–52.
33. Carrillo A, Ferrer M, Gonzalez-Diaz G, Lopez-Martinez A, Llanas N, Alcazar M, et al. Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(12):1279–85.
34. Thille AW, Contou D, Fragnoli C, Cordoba-Izquierdo A, Boissier F, Brun-Buisson C. Non-invasive ventilation for acute hypoxic respiratory failure: intubation rate and risk factors. Crit Care. 2013;17(6):R269.
35. Ozsançak Ugurlu A, Sidhom SS, Khodabandeh A, leong M, Mohr C, Lin DY, et al. Use and outcomes of noninvasive positive pressure ventilation in acute care hospitals in Massachusetts. Chest. 2014;145(5):964–71.
36. Cartaiaux G, Millan-Guiart T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of noninvasive ventilation for de novo acute hypoxic respiratory failure: role of tidal volume. Crit Care Med. 2015.
37. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2014;370(10):980.
38. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med. 2000;342(18):1301–8.
39. Serpa Neto A, Cardoso SO, Manetta JA, Pereira VG, Esposito DC, Pasqua-Lucci M, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA. 2012;308(16):1651–9.
40. The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.
41. Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. 2004;350(24):2452–60.
42. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llanas N, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med. 2012;38(3):458–66.
43. L’Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. Am J Respir Crit Care Med. 2000;342(18):1301–8.
44. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385(9974):1206–18.